FDAnews
www.fdanews.com/articles/202099-pfizerbiontech-evaluate-covid-19-shot-in-kids-aged-6-months-to-11-years-old

Pfizer/BioNTech Evaluate COVID-19 Shot in Kids Aged 6 Months to 11 Years Old

March 30, 2021

The Pfizer/BioNTech COVID-19 vaccine is being assessed in a newly launched study in children as young as six months old.

The companies have begun a clinical trial of their COVID-19 vaccine in children six months to 11 years old, with phase 1 expected to enroll 144 participants. The study will initially seek to identify the preferred dose level (10, 20 or 30 micrograms) in three age groups ― five to 11 years, two to five years and six months to two years.

Once the dose level is confirmed, the phase 2/3 portion of the study will enroll up to 4,500 participants who will receive either the vaccine or a placebo, a Pfizer spokesperson told FDAnews.

View today's stories